What are the most effective antiaging prescription treatments available?
No medicine is approved to treat ageing, so the most effective anti-ageing prescriptions are the ones proven for a specific part of it. For looking older: tretinoin cream, Botox-type injections and fillers have the trials. For living longer: blood-pressure and cholesterol medicines have reduced deaths in trials. For metabolic ageing: GLP-1 drugs have heart-outcome data in people with existing disease. The drugs prescribed for 'ageing' itself — rapamycin, metformin for non-diabetics, hormones, senolytics — have no such evidence.
No prescription treatment is approved to treat ageing, so 'most effective' has to be answered by what each is proven to do to a specific, measurable aspect of it. Ranked on randomised human evidence: for visible skin ageing, tretinoin (decades of trials on photoageing) and botulinum toxin and hyaluronic-acid fillers (approved, with trial evidence for the lines and volume they treat) are the most effective prescriptions available; for the ageing that shortens life, antihypertensives and statins are the most effective anti-ageing prescriptions ever tested, with mortality reductions in trials; for metabolic ageing, GLP-1 agonists have cardiovascular outcome data in people with established disease. Below that line sit the prescriptions written for ageing itself — rapamycin, metformin in non-diabetics, off-label hormones, senolytics — which have no human trial showing an ageing outcome and, for rapamycin, a Phase 3 failure of the closest analogue. The most effective anti-ageing prescription is the one for the thing that is actually measured, taken for the reason it was approved.
- There is no approved anti-ageing drug and no regulatory pathway for one; every 'anti-ageing prescription' is approved for something else or for nothing.
- The prescriptions with the largest effect on how long you live are boring: blood-pressure and cholesterol drugs, with mortality reductions in randomised trials.
- The prescriptions with the largest effect on how old you look are tretinoin and neuromodulators, with decades of trial evidence for the specific changes they treat.
- The prescriptions written for 'ageing' — rapamycin, metformin, hormone 'optimisation', senolytics — are the ones with the least evidence, and the ones telehealth sells most.
- Every drug here has an interaction profile; the off-label ones are prescribed to people who are often taking the on-label ones.
Anti-ageing prescriptions ranked on human evidence
Ranked on: randomised human evidence that the drug changes a measurable consequence of ageing — appearance, a disease event, mortality — in the population it is prescribed to. Approval for a different disease does not raise a drug's grade for anti-ageing use; a mechanism does not either.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Antihypertensives to target | The most effective anti-ageing prescription ever tested | GRADE AEstablished |
| 2 | Statins and other ApoB-lowering therapy | Fewer events and deaths, in a meta-analysis of 26 trials | GRADE AEstablished |
| 3 | Tretinoin (topical retinoid) | Decades of randomised trials on photoageing | GRADE AEstablished |
| 4 | Botulinum toxin (neuromodulators) | Approved and trialled for dynamic lines | GRADE AEstablished |
| 5 | Hyaluronic-acid dermal fillers | Approved devices with trial evidence for volume | GRADE BPromising |
| 6 | GLP-1 receptor agonists (semaglutide and relatives) | Cardiovascular outcome data — in a specific population | GRADE AEstablished |
| 7 | Hormone replacement therapy, for symptoms, in the window | Evidence for symptoms and bone; not for ageing | GRADE BPromising |
| 8 | Metformin in people without diabetes | The most-cited trial has never enrolled anyone | GRADE CEarly |
| 9 | Rapamycin, off-label for ageing | The closest analogue failed its Phase 3 | GRADE CEarly |
| 10 | Senolytics (dasatinib + quercetin, fisetin) | Markers move; the Phase 2 trials missed | GRADE DInsufficient or unsafe |
| 11 | Growth hormone for anti-ageing | A federal felony in the US, and harmful | GRADE DInsufficient or unsafe |
- 01
Antihypertensives to target
GRADE AEstablishedThe most effective anti-ageing prescription ever testedTreating blood pressure to target reduced cardiovascular events and all-cause mortality in randomised trials of older adults at elevated risk. Cardiovascular disease is the leading way ageing kills, and this is the prescription with the strongest evidence against it. Nobody markets it as anti-ageing because it is generic.
- 02
Statins and other ApoB-lowering therapy
GRADE AEstablishedFewer events and deaths, in a meta-analysis of 26 trialsEach unit of LDL lowering reduced major vascular events and all-cause mortality across 170,000 trial participants. For anyone with elevated ApoB, the most effective prescription against the ageing that matters most. Interacts with grapefruit and some antifungals; CoQ10 for muscle symptoms has inconsistent evidence.
- 03
Tretinoin (topical retinoid)
GRADE AEstablishedDecades of randomised trials on photoageingReduces fine wrinkles, roughness and mottled pigmentation in randomised, histologically confirmed trials over months, with a known and manageable irritation profile. The most effective prescription for visible skin ageing, and the one most often replaced by less-evidenced cosmetics.
- 04
Botulinum toxin (neuromodulators)
GRADE AEstablishedApproved and trialled for dynamic linesApproved for glabellar, forehead and lateral canthal lines on randomised trials measuring line severity, with a well-characterised safety profile in trained hands. Effective for what it treats — expression lines — for three to four months per treatment. Not a treatment for skin quality or static ageing.
- 05
Hyaluronic-acid dermal fillers
GRADE BPromisingApproved devices with trial evidence for volumeApproved for specific facial areas on controlled trials measuring volume and wrinkle severity, reversible with hyaluronidase. Effective for volume loss; technique-dependent, with vascular complications that make the injector matter more than the product. Grade B for the dependence on operator and the shorter, less standardised trials than neuromodulators.
- 06
GLP-1 receptor agonists (semaglutide and relatives)
GRADE AEstablishedCardiovascular outcome data — in a specific populationSemaglutide reduced major cardiovascular events in 17,604 adults with overweight or obesity and established cardiovascular disease. That is the strongest human data in the anti-ageing field, and it measured no ageing biology and enrolled no healthy people. Grade A for its population; prescribed to a healthy fifty-year-old for 'metabolic ageing', it is an extrapolation.
- 07
Hormone replacement therapy, for symptoms, in the window
GRADE BPromisingEvidence for symptoms and bone; not for ageingMenopausal hormone therapy has randomised evidence for vasomotor symptoms and fracture reduction, with risks that depend on age at initiation and formulation. Testosterone for diagnosed hypogonadism has trial evidence for symptoms and bone density. Neither is evidence for 'anti-ageing'; hormone 'optimisation' in people without a deficiency has no outcome trial and known harms.
Metformin is an excellent diabetes drug with outcome evidence in that disease. As an anti-ageing prescription for non-diabetics it rests on cohort associations and the TAME trial, which after eleven years remains unfunded and un-started. It also blunts some exercise adaptations in trials. Grade C for an approved drug in an unstudied use.
Replicated lifespan extension in mice; in humans, small trials on immune markers and a Phase 3 of the related mTOR inhibitor RTB101 in 1,024 older adults that hit its target and failed its clinical endpoint. Prescribed weekly by telehealth to healthy people on the strength of the mice. Immunosuppressant with metabolic and mouth-ulcer effects; interacts with many common drugs.
- 10
Senolytics (dasatinib + quercetin, fisetin)
GRADE DInsufficient or unsafeMarkers move; the Phase 2 trials missedSenescent-cell markers fall in small human studies; the Phase 2 bone trial in postmenopausal women missed its primary endpoint and a Phase 2 in osteoarthritis failed against placebo. Dasatinib is a chemotherapy drug with a real adverse-event profile. Prescribed for ageing on the basis of a mechanism.
- 11
Growth hormone for anti-ageing
GRADE DInsufficient or unsafeA federal felony in the US, and harmfulDistributing or prescribing human growth hormone for anti-ageing or enhancement is a federal offence in the United States, and trials in older adults show fluid retention, joint pain, glucose intolerance and no functional benefit. Ranks last for evidence, safety and legality together.
Two kinds of anti-ageing prescription
Prescribed for a consequence of ageing versus prescribed for ageing
| Prescription | Approved for | Trial outcome | Prescribed for 'ageing'? | Evidence for that use |
|---|---|---|---|---|
| Antihypertensives | Hypertension | Fewer events and deaths | Rarely marketed so | Strong — this is what ageing does |
| Statins | Hyperlipidaemia, risk reduction | Fewer events and deaths | Rarely marketed so | Strong |
| Tretinoin | Acne; photodamage (some formulations) | Fewer wrinkles, better texture | Yes, on-label for photoageing | Strong |
| Botulinum toxin | Dynamic facial lines | Line severity | Yes, on-label | Strong for the lines |
| GLP-1 agonists | Diabetes; obesity; CV risk with disease | Fewer CV events in that population | Increasingly | Strong in its population; none in healthy adults |
| HRT / testosterone | Menopausal symptoms; hypogonadism | Symptoms, bone | Yes — 'optimisation' | None for ageing; harms without deficiency |
| Metformin | Type 2 diabetes | Glycaemic and outcome benefit in diabetes | Yes, off-label | Cohort data; TAME never started |
| Rapamycin | Transplant rejection; rare diseases | Immunosuppression | Yes, off-label | Mouse lifespan; human Phase 3 analogue failed |
| Senolytics | Dasatinib: leukaemia | — | Yes, off-label | Phase 2 trials missed |
| Growth hormone | GH deficiency | — | Yes, unlawfully | Harm shown; felony in the US |
Frequently asked questions
What are the most effective anti-ageing prescription treatments?
Ranked on randomised human evidence for a measured outcome: antihypertensives and statins for the ageing that shortens life (fewer events and deaths in trials); tretinoin, botulinum toxin and hyaluronic-acid fillers for visible skin ageing (trials on wrinkles, lines and volume); GLP-1 agonists for metabolic ageing in people with established cardiovascular disease. Rapamycin, metformin in non-diabetics, hormone 'optimisation', senolytics and growth hormone are prescribed for ageing itself and have no human trial showing an ageing outcome.
Is there an approved anti-ageing drug?
No. No drug is approved by the FDA, the EMA or any regulator to treat ageing, and no regulatory pathway for such an approval exists. Every anti-ageing prescription is either approved for a specific consequence of ageing — hypertension, photodamage, dynamic lines — or prescribed off-label for ageing without evidence for that use.
Is rapamycin an effective anti-ageing prescription?
Not on human evidence. It extends lifespan in mice in replicated studies; in humans there are small trials on immune markers and a Phase 3 of the related mTOR inhibitor RTB101 in 1,024 older adults that hit its molecular target and failed its clinical endpoint. It is an immunosuppressant with metabolic effects and many drug interactions, prescribed weekly by telehealth to healthy people on the strength of the mice.
Does metformin slow ageing?
It has not been shown to. Metformin has outcome evidence in type 2 diabetes; for non-diabetics the anti-ageing case rests on cohort associations and the TAME trial, which eleven years after its endpoint agreement has never enrolled a participant. Trials also show it blunts some adaptations to exercise. An excellent diabetes drug in an unstudied use.
What is the most effective prescription for wrinkles?
Tretinoin for fine wrinkles, texture and pigmentation from photoageing, with decades of randomised trials; botulinum toxin for dynamic expression lines, approved on trials measuring line severity; hyaluronic-acid fillers for volume loss. Each treats a different component of visible ageing, and each is far better evidenced than any cosmetic or peptide.
Are GLP-1 drugs anti-ageing treatments?
They have the strongest human outcome data in the field — semaglutide reduced cardiovascular events in 17,604 people with overweight or obesity and established cardiovascular disease — and that trial measured no ageing biology and enrolled no healthy people. Effective for their approved population; prescribed to a healthy adult for 'metabolic ageing', an extrapolation.
Keep reading
- Anti-aging pharmaceuticals: what has actually been tested in people
The full section: RTB101, TAME, senolytic trials, GLP-1 SELECT and the regulatory picture.
- Which antiaging medicines deliver clinically proven wrinkle reduction results?
The skin prescriptions in detail.
- Rapamycin
The compound page, with the RTB101 result.
- Free stack check
If rapamycin, metformin or a senolytic is already in your regimen, screen it against the rest.
More in Anti-aging pharma
- Rapamycin for longevity: what the human evidence actually shows
The only 48-week human trial (PEARL, n=129) missed its primary endpoint. What rapamycin has actually shown, the real risks, and who should never take it.
- Which antiaging medicines deliver clinically proven wrinkle reduction results?
Medicines with clinically proven wrinkle reduction, ranked on randomised trials: botulinum toxin for dynamic lines, tretinoin and tazarotene for photoageing wrinkles, hyaluronic-acid fillers for folds, adapalene, then the over-the-counter retinol and peptides — and why sunscreen underwrites all of them.
- What antiaging pharmaceuticals work best for skin rejuvenation?
Anti-ageing pharmaceuticals for skin rejuvenation ranked on randomised evidence across texture, pigmentation, lines and volume: tretinoin, hydroquinone and tranexamic acid, botulinum toxin, fillers, azelaic acid, adapalene, oral isotretinoin (low-dose) — and the systemic drugs that do nothing for skin.
- Which doctor-prescribed antiaging drugs are safest long term?
Doctor-prescribed anti-ageing drugs ranked on long-term safety data: statins and antihypertensives (decades, millions), topical tretinoin, menopausal HRT in the window, GLP-1 agonists (years), metformin off-label, low-dose rapamycin, senolytics, testosterone 'optimisation' and growth hormone — with what is actually known about each over years.
- How do I choose a medical-grade antiaging treatment plan?
A ranked method for choosing a medical-grade anti-ageing treatment plan: measure first, treat what is measured, prefer on-label evidence, separate skin from systemic, demand monitoring, price the plan honestly — and the clinic-menu features that mean it is not medical-grade at all.
- What antiaging medications should I discuss with my dermatologist?
The anti-ageing medications worth raising with a dermatologist, ranked by how much the prescription adds over what you can buy: tretinoin, hydroquinone and tranexamic acid, neuromodulators and fillers, tazarotene, azelaic acid, low-dose isotretinoin — and what to bring to the appointment.